CoChat
Sign Up
Cited by 126Nanoparticle-Based Drug DeliveryAdvanced Drug Delivery SystemsExtracellular vesicles in disease

Recent Advances in Macrophage-Mediated Drug Delivery Systems

Open access
Liang, Tiantian, Zhang, Rongtao, Liu, Xianbin, Ding, Qian, Wu, Siqiong, Li, Chunhong, Lin, Yan, Ye, Yun +2 more·2021·International Journal of Nanomedicine
DOI 10.2147/ijn.s298159PMC PMC8039204
Open this paper in CoChat — free accountOpen PDF

Abstract

Macrophages have been extensively used in the development of drug delivery systems, as they can prolong the circulation and release of drugs, extend their half-life, increase their stability and targeting ability, and reduce immunogenicity. Moreover, they have good biocompatibility and degradability and offer abundant surface receptors for targeted delivery of a wide variety of drugs. Macrophage-mediated drug delivery systems can be prepared by loading drugs or drug-loaded nanoparticles into macrophages, macrophage membranes or macrophage-derived vesicles. Although such systems can be used to treat inflammation, cancer, HIV infection and other diseases, they require further research and optimization since they have been assembled from diverse sources and therefore can have quite different physical and chemical properties. Moreover, potential cell-drug interactions can limit their application, and the biological activity of membrane proteins might be lost during membrane extraction and storage. In this review, we summarize the recent advances in this field and discuss the preparation of macrophage-mediated drug delivery systems, their advantages over other delivery systems, their potential applications and future lines of research.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/ijn.s298159

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Macrophage-based drug delivery harnesses prolonged circulation time, abundant surface receptors, and active targeting ability under specific phenotype.

    “the macrophage-based strategy for drug delivery harnesses the prolonged circulation time, abundant surface receptors, and active targeting ability of macrophages under specific phenotype.”

    From The blood–brain barrier: Structure, regulation and drug delivery (2023) · cites this paper as [203]

    The Introduction (page not provided) explicitly says macrophage-based delivery systems harness long circulation time, abundant surface receptors, and active targeting. The paper discusses an M1 phenotype in an anti-tumor application, but it does not tie all three stated advantages to a specific phenotype. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 78

  1. [1]Patra JK, Das G, Fraceto LF, et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnol. 2018; 16. doi: 10.1186/s12951-018-0392-8 PMC6145203 30231877 · DOI
  2. [2]García KP, Zarschler K, Barbaro L, et al. Zwitterionic coatings: zwitterionic-coated “stealth” nanoparticles for biomedical applications: recent advances in countering biomolecular corona formation and uptake by the mononuclear phagocyte system. Small. 2014; 13: 2516– 2529. doi: 10.1002/smll.201303540 24687857 · DOI
  3. [3]Tsoi KM, Macparland SA, Ma X-Z, et al. Mechanism of hard-nanomaterial clearance by the liver. Nat Mater. 2016; 15(11): 1212– 1221. doi: 10.1038/nmat4718 27525571 PMC5132626 · DOI
  4. [4]Kolate A, Baradia D, Patil S, et al. PEG — a versatile conjugating ligand for drugs and drug delivery systems. J Control Release. 2014; 192: 67– 81. doi: 10.1016/j.jconrel.2014.06.046 24997275 · DOI
  5. [5]Li C, Wang X, Li R, et al. Resveratrol-loaded PLGA nanoparticles functionalized with red blood cell membranes as a biomimetic delivery system for prolonged circulation time. J Drug Deliv Sci Technol. 2019; 54: 101369. doi: 10.1016/j.jddst.2019.101369 · DOI
  6. [6]Zhang Z, Chu Y, Li C, et al. Anti-PEG scFv corona ameliorates accelerated blood clearance phenomenon of PEGylated nanomedicines. J Control Release. 2020; 330: 493– 501. doi: 10.1016/j.jconrel.2020.12.047 33383098 · DOI
  7. [7]Elsadek NE, Lila ASA, Emam SE, et al. Pegfilgrastim (PEG-G-CSF) induces anti-PEG IgM in a dose dependent manner and causes the accelerated blood clearance (ABC) phenomenon upon repeated administration in mice. Eur J Pharm Biopharm. 2020; 152: 56– 62. doi: 10.1016/j.ejpb.2020.04.026 32376372 · DOI
  8. [8]Ayer M, Klok HA. Cell-mediated delivery of synthetic nano- and microparticles. J Control Release. 2017; 259: 92– 104. doi: 10.1016/j.jconrel.2017.01.048 28189629 · DOI
  9. [9]Yu H, Yang Z, Li F, Xu L, Sun Y. Cell-mediated targeting drugs delivery systems. Drug Deliv. 2020; 27(1): 1425– 1437. doi: 10.1080/10717544.2020.1831103 33096949 PMC7594730 · DOI
  10. [10]Anselmo AC, Mitragotri S. Cell-mediated delivery of nanoparticles: taking advantage of circulatory cells to target nanoparticles. J Control Release. 2014; 190: 531– 541. doi: 10.1016/j.jconrel.2014.03.050 24747161 PMC4142097 · DOI
  11. [11]Hu CMJ, Zhang L, Aryal S, Cheung C, Fang RH, Zhang L. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc Natl Acad Sci U S A. 2011; 108(27): 10980– 10985. doi: 10.1073/pnas.1106634108 21690347 PMC3131364 · DOI
  12. [12]Rao L, Bu LL, Xu JH, et al. Red blood cell membrane as a biomimetic nanocoating for prolonged circulation time and reduced accelerated blood clearance. Small. 2015; 11(46): 6225– 6236. doi: 10.1002/smll.201502388 26488923 · DOI
  13. [14]Tacke F. Targeting hepatic macrophages to treat liver diseases. J Hepatol. 2017; 66(6): 1300– 1312. doi: 10.1016/j.jhep.2017.02.026 28267621 · DOI · Paper page
  14. [17]Guo Q, Zhichao J, Yuan Y, et al. New mechanisms of tumor-associated macrophages on promoting tumor progression: recent research advances and potential targets for tumor immunotherapy. J Immunol Res. 2016; 2016: 9720912. doi: 10.1155/2016/9720912 27975071 PMC5128713 · DOI
  15. [18]Dou H, Destache CJ, Morehead JR, et al. Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood. 2006; 108: 2827– 2835. doi: 10.1182/blood-2006-03-012534 16809617 PMC1895582 · DOI
  16. [19]Choi MR, Stanton-Maxey KJ, Stanley JK, et al. A cellular trojan horse for delivery of therapeutic nanoparticles into tumors. Nano Lett. 2007; 7(12): 3759– 3765. doi: 10.1021/nl072209h 17979310 · DOI
  17. [20]Batrakova EV, Li S, Reynolds AD, et al. A macrophage-nanozyme delivery system for parkinson’s disease. Bioconjug Chem. 2007; 18: 1498– 1506. doi: 10.1021/bc700184b 17760417 PMC2677172 · DOI
  18. [21]Parodi A, Quattrocchi N, Van D, et al. Biomimetic functionalization with leukocyte membranes imparts cell like functions to synthetic particles. Nat Nanotechnol. 2013; 8(1): 61. doi: 10.1038/nnano.2012.212 23241654 PMC3751189 · DOI
  19. [22]Wayne EC, Long C, Haney MJ, et al. Targeted delivery of siRNA lipoplexes to cancer cells using macrophage transient horizontal gene transfer. Adv Sci. 2019; 6(21): 1900582. doi: 10.1002/advs.201900582 PMC6839649 31728272 · DOI
  20. [23]Li R, He Y, Zhu Y, et al. Route to rheumatoid arthritis by macrophage-derived microvesicle-coated nanoparticles. Nano Lett. 2019; 19(1): 124– 134. doi: 10.1021/acs.nanolett.8b03439 30521345 · DOI
  21. [24]Nowacek AS, Balkundi S, Mcmillan JE, et al. Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages. J Control Release. 2011; 150(2): 204– 211. doi: 10.1016/j.jconrel.2010.11.019 21108978 PMC3065529 · DOI
  22. [25]Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol. 2005; 5(12): 953– 964. doi: 10.1038/nri1733 16322748 · DOI · Paper page
  23. [26]Shi C, Pamer EG. Monocyte recruitment during infection and inflammation. Nat Rev Immunol. 2011; 11(11): 762– 774. doi: 10.1038/nri3070 21984070 PMC3947780 · DOI · Paper page
  24. [27]Zhao Y, Haney MJ, Mahajan V, et al. Active targeted macrophage-mediated delivery of catalase to affected brain regions in models of parkinson’s disease. J Nanomed Nanotechnol. 2011; S4: 003. doi: 10.4172/2157-7439.S4-003 22288024 PMC3267477 · DOI
  25. [28]Evans M, Huang PJ, Iwamoto Y, et al. Macrophage-mediated delivery of light activated nitric oxide prodrugs with spatial, temporal and concentration control. Chem Sci. 2018; 9: 3729– 3741. doi: 10.1039/C8SC00015H 29780505 PMC5939611 · DOI
  26. [29]Madsen SJ, Christie C, Hong SJ, et al. Nanoparticle-loaded macrophage-mediated photothermal therapy: potential for glioma treatment. Laser Med Sci. 2015; 30: 1357– 1365. doi: 10.1007/s10103-015-1742-5 PMC4730872 25794592 · DOI
  27. [30]Choi J, Kim H-Y, Ju EJ, et al. Use of macrophages to deliver therapeutic and imaging contrast agents to tumors. Biomaterials. 2012; 33: 4195– 4203. doi: 10.1016/j.biomaterials.2012.02.022 22398206 · DOI
  28. [31]Nguyen VD, Min HK, Kim DH, et al. Macrophage-mediated delivery of multifunctional nanotherapeutics for synergistic chemo-photothermal therapy of solid tumors. ACS Appl Mater Interfaces. 2020; 12(9): 10130– 10141. doi: 10.1021/acsami.9b23632 32041404 · DOI
  29. [32]Cao X, Tan T, Zhu D, et al. Paclitaxel-loaded macrophage membrane camouflaged albumin nanoparticles for targeted cancer therapy. Int J Nanomedicine. 2020; 15: 1915– 1928. doi: 10.2147/IJN.S244849 32256068 PMC7090179 · DOI
  30. [33]Zhou X, Luo B, Kang K, et al. Leukocyte-repelling biomimetic immunomagnetic nanoplatform for high-performance circulating tumor cells isolation. Small. 2019; 15(17): e1900558. doi: 10.1002/smll.201900558 30932344 · DOI
  31. [34]He W, Frueh J, Wu Z, He Q. Leucocyte membrane-coated janus microcapsules for enhanced photothermal cancer treatment. Langmuir. 2016; 32(15): 3637– 3644. doi: 10.1021/acs.langmuir.5b04762 27023433 · DOI
  32. [35]Xuan M, Shao J, Dai L, Li J, He Q. Macrophage cell membrane camouflaged Au nanoshells for in vivo prolonged circulation life and enhanced cancer photothermal therapy. ACS Appl Mater Interfaces. 2016; 8(15): 9610– 9618. doi: 10.1021/acsami.6b00853 27039688 · DOI
  33. [36]Su H, Wang Y, Gu Y, Bowman L, Zhao J, Ding M. Potential applications and human biosafety of nanomaterials used in nanomedicine. J Appl Toxicol. 2018; 38(1): 3– 24. doi: 10.1002/jat.3476 28589558 PMC6506719 · DOI
  34. [37]Meng QF, Rao L, Zan M, et al. Macrophage membrane-coated iron oxide nanoparticles for enhanced photothermal tumor therapy. Nanotechnology. 2018; 29(13): 134004. doi: 10.1088/1361-6528/aaa7c7 29334363 · DOI
  35. [38]Xuan M, Shao J, Dai L, He Q, Li J. Macrophage cell membrane camouflaged mesoporous silica nanocapsules for in vivo cancer therapy. Adv Healthc Mater. 2015; 4(11): 1645– 1652. doi: 10.1002/adhm.201500129 25960053 · DOI
  36. [39]Casares D, Escribá PV, Rosselló CA. Membrane lipid composition: effect on membrane and organelle structure, function and compartmentalization and therapeutic avenues. Int J Mol Sci. 2019; 20(9): 2167. doi: 10.3390/ijms20092167 PMC6540057 31052427 · DOI
  37. [40]Dong X, Chu D, Wang Z. Leukocyte-mediated delivery of nanotherapeutics in inflammatory and tumor sites. Theranostics. 2017; 7(3): 751– 763. doi: 10.7150/thno.18069 28255364 PMC5327647 · DOI
  38. [41]Thamphiwatana S, Angsantikul P, Escajadillo T, et al. Macrophage-like nanoparticles concurrently absorbing endotoxins and proinflammatory cytokines for sepsis management. Proc Natl Acad Sci U S A. 2017; 114(43): 11488– 11493. doi: 10.1073/pnas.1714267114 29073076 PMC5664555 · DOI
  39. [42]Combes F, Meyer E, Sanders NN. Immune cells as tumor drug delivery vehicles. J Control Release. 2020; 327: 70– 87. doi: 10.1016/j.jconrel.2020.07.043 32735878 · DOI
  40. [43]Choi M-R, Bardhan R, Stanton-Maxey KJ, et al. Delivery of nanoparticles to brain metastases of breast cancer using a cellular trojan horse. Cancer Nanotechnol. 2012; 3(1–6): 47– 54. doi: 10.1007/s12645-012-0029-9 23205151 PMC3505533 · DOI
  41. [44]Cao H, Dan Z, He X, et al. Liposomes coated with isolated macrophage membrane can target lung metastasis of breast cancer. ACS Nano. 2016; 10(8): 7738– 7748. doi: 10.1021/acsnano.6b03148 27454827 · DOI
  42. [45]Rao L, He Z, Meng QF, et al. Effective cancer targeting and imaging using macrophage membrane-camouflaged upconversion nanoparticles. J Biomed Mater Res A. 2017; 105(2): 521– 530. doi: 10.1002/jbm.a.35927 27718539 · DOI
  43. [46]Srirupa B, Sankar GS. Transmembrane TNFα-expressed macrophage membrane-coated chitosan nanoparticles as cancer therapeutics. ACS Omega. 2020; 5: 1572– 1580. doi: 10.1021/acsomega.9b03531 32010831 PMC6990626 · DOI
  44. [47]Doshi N, Swiston AJ, Gilbert JB, et al. Cell-based drug delivery devices using phagocytosis-resistant backpacks. Adv Mater. 2011; 23(12): H105– H109. doi: 10.1002/adma.201004074 21365691 · DOI
  45. [48]Klyachko NL, Polak R, Haney MJ, et al. Macrophages with cellular backpacks for targeted drug delivery to the brain. Biomaterials. 2017; 140: 79– 87. doi: 10.1016/j.biomaterials.2017.06.017 28633046 PMC5605925 · DOI
  46. [49]Lee S. Monocytes: a novel drug delivery system targeting atherosclerosis. J Drug Target. 2014; 22(2): 138– 145. doi: 10.3109/1061186X.2013.844158 24117054 · DOI
  47. [50]Evangelopoulos M, Yazdi IK, Acciardo S, et al. Biomimetic cellular vectors for enhancing drug delivery to the lungs. Sci Rep. 2020; 10(1): 172. doi: 10.1038/s41598-019-55909-x 31932600 PMC6957529 · DOI
  48. [51]Lemke G. How macrophages deal with death. Nat Rev Immunol. 2019; 19(9): 539– 549. doi: 10.1038/s41577-019-0167-y 31019284 PMC6733267 · DOI
  49. [52]Zhang Y, Cai K, Li C, et al. Macrophage-membrane-coated nanoparticles for tumor-targeted chemotherapy. Nano Lett. 2018; 18(3): 1908– 1915. doi: 10.1021/acs.nanolett.7b05263 29473753 PMC7470025 · DOI
  50. [53]Haney MJ, Zhao Y, Jin YS, et al. Macrophage-derived extracellular vesicles as drug delivery systems for triple negative breast cancer (TNBC) therapy. J Neuroimmune Pharmacol. 2019; 15: 2. doi: 10.1007/s11481-019-09884-9 31722094 · DOI
  51. [54]Rayamajhi S, Nguyen TDT, Marasini R, Aryal S. Macrophage-derived exosome-mimetic hybrid vesicles for tumor targeted drug delivery. Acta Biomater. 2019; 94: 482– 494. doi: 10.1016/j.actbio.2019.05.054 31129363 · DOI · Paper page
  52. [55]Molinaro R, Pastò A, Corbo C, et al. Macrophage-derived nanovesicles exert intrinsic anti-inflammatory properties and prolong survival in sepsis through a direct interaction with macrophages. Nanoscale. 2019; 11(28): 13576– 13586. doi: 10.1039/c9nr04253a 31290914 · DOI
  53. [56]Tang TT, Lv LL, Wang B, et al. Employing macrophage-derived microvesicle for kidney-targeted delivery of dexamethasone: an efficient therapeutic strategy against renal inflammation and fibrosis. Theranostics. 2019; 9(16): 4740– 4755. doi: 10.7150/thno.33520 31367254 PMC6643445 · DOI
  54. [57]Arneth B. Tumor microenvironment. Medicina. 2019; 56(1): 15. doi: 10.3390/medicina56010015 PMC7023392 31906017 · DOI
  55. [58]Zhang W, Wang M, Tang W, et al. Nanoparticle-laden macrophages for tumor-tropic drug delivery. Adv Mater. 2018; 30(50): e1805557. doi: 10.1002/adma.201805557 30368972 PMC6506271 · DOI
  56. [59]Kim MS, Haney MJ, Zhao Y, et al. Engineering macrophage-derived exosomes for targeted paclitaxel delivery to pulmonary metastases: in vitro and in vivo evaluations. Nanomedicine. 2017; 14(1): 195– 204. doi: 10.1016/j.nano.2017.09.011 28982587 · DOI · Paper page
  57. [60]Ngambenjawong C, Gustafson HH, Pun SH. Progress in tumor-associated macrophage (TAM)-targeted therapeutics. Adv Drug Deliv Rev. 2017; 114: 206– 221. doi: 10.1016/j.addr.2017.04.010 28449873 PMC5581987 · DOI
  58. [61]Wu K, Lin K, Li X, et al. Redefining tumor-associated macrophage subpopulations and functions in the tumor microenvironment. Front Immunol. 2020; 11: 1731. doi: 10.3389/fimmu.2020.01731 32849616 PMC7417513 · DOI
  59. [62]Zheng Y, Bao J, Zhao Q, Zhou T, Sun X. A spatio-temporal model of macrophage-mediated drug resistance in glioma immunotherapy. Mol Cancer Ther. 2018; 17(4): 814– 824. doi: 10.1158/1535-7163.MCT-17-0634 29440290 · DOI
  60. [63]Zhang J, Guan M, Wang Q, Zhang J, Zhou T, Sun X. Single-cell transcriptome-based multilayer network biomarker for predicting prognosis and therapeutic response of gliomas. Brief Bioinform. 2020; 21(3): 1080– 1907. doi: 10.1093/bib/bbz040 31329830 · DOI
  61. [64]Sun X, Liu X, Xia M, Shao Y, Zhang XD. Multicellular gene network analysis identifies a macrophage-related gene signature predictive of therapeutic response and prognosis of gliomas. J Transl Med. 2019; 17(1): 159. doi: 10.1186/s12967-019-1908-1 31097021 PMC6524242 · DOI
  62. [65]Fu J, Wang D, Dong M, et al. Macrophage mediated biomimetic delivery system for the treatment of lung metastasis of breast cancer. J Control Release. 2015; 204: 11– 19. doi: 10.1016/j.jconrel.2015.01.039 25646783 · DOI
  63. [66]Zhao H, Zhang J, Zheng C, et al. C–C chemokine ligand 2 (CCl2) recruits macrophage-membrane-camouflaged hollow bismuth selenide nanoparticles to facilitate photothermal sensitivity and inhibit lung metastasis of breast cancer. ACS Appl Mater Interfaces. 2018; 10(37): 31124– 31135. doi: 10.1021/acsami.8b11645 30141614 · DOI
  64. [67]Pang L, Zhu Y, Qin J, Zhao W, Wang J. Primary M1 macrophages as multifunctional carrier combined with PLGA nanoparticle delivering anticancer drug for efficient glioma therapy. Drug Deliv. 2018; 25(1): 1922– 1931. doi: 10.1080/10717544.2018.1502839 30465444 PMC6263108 · DOI
  65. [68]Liu J, Wu F, Zhou H. Macrophage-derived exosomes in cancers: biogenesis, functions and therapeutic applications. Immunol Lett. 2020; 227: 102– 108. doi: 10.1016/j.imlet.2020.08.003 32888974 · DOI
  66. [69]Wang P, Wang H, Huang Q, et al. Exosomes from M1-polarized macrophages enhance paclitaxel antitumor activity by activating macrophages-mediated inflammation. Theranostics. 2019; 9(6): 1714– 1727. doi: 10.7150/thno.30716 31037133 PMC6485189 · DOI · Paper page
  67. [70]Li J, Li N, Wang J. M1 macrophage-derived exosome-encapsulated cisplatin can enhance its anti-lung cancer effect. Minerva Med. 2020. doi: 10.23736/S0026-4806.20.06564-7 32272830 · DOI
  68. [71]Joan E, Maria B. Iron oxide nanoparticles in photothermal therapy. Molecules. 2018; 23: 1567. doi: 10.3390/molecules23071567 PMC6100614 29958427 · DOI
  69. [72]Cheon YA, Bae JH, Chung BG. Reduced graphene oxide nanosheet for chemo-photothermal therapy. Langmuir. 2016; 32(11): 2731– 2736. doi: 10.1021/acs.langmuir.6b00315 26930106 · DOI
  70. [73]Han S, Kwon T, Um JE, Haam S, Kim WJ. Highly selective photothermal therapy by a phenoxylated-dextran-functionalized smart carbon nanotube platform. Adv Healthc Mater. 2016; 5(10): 1147– 1156. doi: 10.1002/adhm.201600015 27029602 · DOI
  71. [74]Choi WI, Sahu A, Kim YH, Tae G. Photothermal cancer therapy and imaging based on gold nanorods. Ann Biomed Eng. 2012; 40(2): 534– 546. doi: 10.1007/s10439-011-0388-0 21887589 · DOI
  72. [75]Qiang L, Cai Z, Jiang W, et al. A novel macrophage-mediated biomimetic delivery system with NIR-triggered release for prostate cancer therapy. J Nanobiotechnology. 2019; 17: 83– 98. doi: 10.1186/s12951-019-0513-z 31291948 PMC6617631 · DOI
  73. [76]Dou H, Grotepas CB, McMillan JM, et al. Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of NeuroAIDS. J Immunol. 2009; 183(1): 661– 669. doi: 10.4049/jimmunol.0900274 19535632 PMC2765254 · DOI
  74. [77]Haney MJ, Klyachko NL, Zhao Y, et al. Exosomes as drug delivery vehicles for parkinson’s disease therapy. J Control Release. 2015; 207: 18– 30. doi: 10.1016/j.jconrel.2015.03.033 25836593 PMC4430381 · DOI · Paper page
  75. [78]Wang C, Wang Y, Zhang L, et al. Pretreated macrophage-membrane-coated gold nanocages for precise drug delivery for treatment of bacterial infections. Adv Mater. 2018; 30(46): e1804023. doi: 10.1002/adma.201804023 30285289 · DOI
  76. [79]Peng R, Ji H, Jin L, et al. Macrophage-based therapies for atherosclerosis management. J Immunol Res. 2020; 2020: 8131754. doi: 10.1155/2020/8131754 32411803 PMC7204102 · DOI
  77. [80]Gao C, Huang Q, Liu C, et al. Treatment of atherosclerosis by macrophage-biomimetic nanoparticles via targeted pharmacotherapy and sequestration of proinflammatory cytokines. Nat Commun. 2020; 11(1): 2622. doi: 10.1038/s41467-020-16439-7 32457361 PMC7251120 · DOI
  78. [81]Kumar P, Bose PP. Macrophage ghost entrapped amphotericin B: a novel delivery strategy towards experimental visceral leishmaniasis. Drug Deliv Transl Res. 2018; 9: 249– 259. doi: 10.1007/s13346-018-00602-1 30430452 · DOI

Cited by

Sorted by citations

Authors
Liang, T., Zhang, R., Liu, X., Ding, Q., Wu, S., Li, C., Lin, Y., Ye, Y., Zhong, Z., & Zhou, M.
Affiliations
Southwest Medical University (CN)
Corresponding author
Zhou, Meiling
ORCID
Venue
International Journal of Nanomedicine
Publisher
Informa UK Limited
Published
2021-04
Volume
Volume 16
Pages
2703-2714
ISSN
  • 1176-9114 (ISSN-L)
  • 1178-2013
DOI
10.2147/ijn.s298159
PMC
PMC8039204
OpenAlex
W3140646945
Cited by
126
References
3
Citations by year
2026: 15 · 2025: 28 · 2024: 31 · 2023: 34 · 2022: 13 · 2021: 5
FWCI
1.43
Type
journal article
Language
en
Open access
Licence
Locations
  • International Journal of Nanomedicine (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
Funders
Southwest Medical University (2018LZXNYD-PT02, 2019ZZD020)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
Keywords
macrophage-derived vesicles, drug-loaded nanoparticles, targeted drug delivery, drug half-life extension, immunogenicity reduction, inflammation, cancer, HIV infection
MeSH terms
Photothermal Therapy, Humans, Macrophages, Neoplasms, HIV Infections, Drug Delivery Systems, Nanoparticles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review